269 related articles for article (PubMed ID: 22081052)
1. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
Tominaga K; Iwakiri R; Fujimoto K; Fujiwara Y; Tanaka M; Shimoyama Y; Umegaki E; Higuchi K; Kusano M; Arakawa T;
J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
[TBL] [Abstract][Full Text] [Related]
3. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
Tominaga K; Kato M; Takeda H; Shimoyama Y; Umegaki E; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Kusano M; Fujimoto K; Arakawa T;
J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.
Sugimoto M; Nishino M; Kodaira C; Yamade M; Uotani T; Ikuma M; Umemura K; Furuta T
World J Gastroenterol; 2011 Apr; 17(14):1858-65. PubMed ID: 21528060
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Fujimoto K; Hongo M;
Intern Med; 2011; 50(3):179-88. PubMed ID: 21297318
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
9. Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole.
Muro Y; Sugiura K; Nitta Y; Mitsuma T; Hoshino K; Usuda T; Hayashi K; Murase Y; Shimizu M; Matsuo H
Clin Exp Rheumatol; 2009; 27(3 Suppl 54):15-21. PubMed ID: 19796556
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Kinoshita Y; Hongo M;
Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.
Ha NY; Kim JW; Kim J
BMC Complement Med Ther; 2023 Dec; 23(1):444. PubMed ID: 38062418
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
Miyamoto M; Manabe N; Haruma K
Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan.
Fujimoto K; Hongo M;
J Gastroenterol; 2010 Dec; 45(12):1193-200. PubMed ID: 20607308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
[TBL] [Abstract][Full Text] [Related]
15. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
16. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
[TBL] [Abstract][Full Text] [Related]
17. Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
Miwa H; Takubo K; Shimatani T; Furuta T; Oshima T; Tanaka J; Aida J; Ito M; Kurosawa S; Joh T; Wada T; Habu Y; Watanabe Y; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol Hepatol; 2013 Mar; 28(3):479-87. PubMed ID: 22989221
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
[TBL] [Abstract][Full Text] [Related]
19. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.
Adachi K; Furuta K; Miwa H; Oshima T; Miki M; Komazawa Y; Iwakiri K; Furuta T; Koike T; Shimatani T; Kinoshita Y
Dig Dis Sci; 2012 Jun; 57(6):1609-17. PubMed ID: 22367114
[TBL] [Abstract][Full Text] [Related]
20. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
